- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04707872
Estudo Trifecta-Heart cfDNA-MMDx
Estudo Trifecta-Heart cfDNA-MMDX: comparando o teste DD-cfDNA com o teste MMDx Microarray e o teste de anticorpo HLA central
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The current standard for assessment of rejection in heart transplants is an endomyocardial biopsy (EMB) interpreted by histology according to ISHLT guidelines. This has considerable error rates, many due to the high disagreement among pathologists in assessing lesions and diagnoses. To address the unmet need for precision and accuracy, the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system - the Molecular Microscope® Diagnostic System (MMDx), which uses microarrays to define the global gene expression features of rejection and injury. Now a new screening test is being introduced: the monitoring of donor-derived cell-free DNA (DD-cfDNA) released in the blood by the heart during rejection. The Natera Inc DD-cfDNA Prospera® test is based on the massively multiplex polymerase chain reaction that targets 13,392 single nucleotide polymorphisms and targeted sequences are quantified by Next Generation Sequencing. The Prospera® test has been done on kidney transplant recipients and detected "active rejection" and differentiated it from borderline rejection and no rejection. However, Prospera® test was not examined (the DD-cfDNA results) in heart transplant recipients. DD-cf-DNA test for heart transplants must now be calibrated against MMDx that is based on global gene expression, the new standard for biopsy interpretation. The present study will calibrate centrally measured (Natera Inc) DD-cfDNA levels obtained at the time of an indication or protocol biopsy against the MMDx measurements of T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and early and late tissue injury. The present study will compare DD-cfDNA and MMDx in 300 prospectively collected biopsies for clinical indications and protocol, and accompanying 600 blood samples, to calibrate the DD-cfDNA (Natera Inc.) levels against the MMDx biopsy diagnoses of TCMR, ABMR (and its stages), and acute (early) and chronic (late) injury, , as well as central assessment of HLA antibody (One Lambda) in 300 blood samples, interpreted centrally as donor specific antibody (DSA) based on the tissue typing results. Trifecta-Heart collected 732 biopsies, 719 cfDNA samples and 706 One Lambda samples so far. Due to a considerable interest from participation centers, this study aims to collect 300 more biopsies and corresponding blood samples. This study is an extension of the INTERHEART ClinicalTrials.gov Identifier: NCT02670408
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Robert Polakowski, PhD
- Número de telefone: 1 780 492 5091
- E-mail: polakows@ualberta.ca
Estude backup de contato
- Nome: Konrad Famulski, PhD
- Número de telefone: 1 780 782 9463
- E-mail: konrad@ualberta.ca
Locais de estudo
-
-
-
Darlinghurst, Austrália, NSW 2010
- Ainda não está recrutando
- Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute
-
Investigador principal:
- Peter MacDonald, MD
-
Contato:
- Carmen Herrera, MD
- E-mail: peter.macdonal@svha.org.au
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 2R7
- Recrutamento
- Division of Cardiology, University of Alberta
-
Investigador principal:
- Daniel Kim, MD
-
Contato:
- Daniel Kim, MD
- E-mail: dk@ualberta.ca
-
-
-
-
-
A Coruña, Espanha
- Ainda não está recrutando
- Advanced Heart Failure Transplant Unit
-
Investigador principal:
- Maria G Crespo-Leiro, MD
-
Contato:
- Zulaika Grille Cancela
- E-mail: Zulaika.grille.cancela@sergas.es
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Recrutamento
- Baptist Health Institute for Research and Innovation
-
Investigador principal:
- Patrick Campbell, MD
-
Contato:
- Victoria McIntosh Marren
- E-mail: victoria.mcintosh@baptist-health.org
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33606
- Recrutamento
- Tampa General Hospital, 409 Bayshore Blvd.
-
Contato:
- Kristyn Kuzianik
- E-mail: kkuzianik@tgh.org
-
Investigador principal:
- Benjamin Mackie, MD
-
-
New Jersey
-
West New York, New Jersey, Estados Unidos, 10032
- Recrutamento
- Columbia University Medical Center, Columbia Interventional Cardiovascular Care
-
Investigador principal:
- Gabriel Sayer, MD
-
Contato:
- Maria Alejandra Muñoz Cifuentes
- E-mail: mam2649@cumc.columbia.edu
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL
-
Contato:
- Renae Robinson
- E-mail: rerobins@montefiore.org
-
Contato:
- Brandon Johnson
- E-mail: brajohnson@montefiore.org
-
Investigador principal:
- Omar Saeed, MD
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Recrutamento
- Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute
-
Contato:
- Aayla K Jamil, MBBS
- E-mail: Aayla.Jamil@BSWHealth.org
-
Investigador principal:
- Shelley Hall, MD
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- Recrutamento
- Cardiovascular Medicine, University of Utah Health
-
Contato:
- Jennifer Hong
- E-mail: Jennifer.Hong@hsc.utah.edu
-
Investigador principal:
- Josef Stehlik, MD, PhD
-
-
-
-
-
Bologna, Itália, 40138
- Ainda não está recrutando
- Heart Failure and Heart Transplant Unit, University of Bologna
-
Investigador principal:
- Luciano Potena, MD
-
Contato:
- Laura Borgese
- E-mail: laura.borgese@gmail.com
-
-
-
-
-
Zabrze, Polônia, 41-800
- Recrutamento
- Silesian Center for Heart Diseases (Ś!ąskie Centrum Chorób Serca w Zabrzu
-
Investigador principal:
- Piotr Przybylowski, Professor
-
Contato:
- Agnieszka Kuczaj, MD PhD
- E-mail: agnieszka.kuczaj@gmail.com
-
-
-
-
-
Prague, Tcheca, 140 21
- Recrutamento
- Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9
-
Contato:
- Tereza Novakowa
- E-mail: novt@ikem.cz
-
Investigador principal:
- Vojtech Melenovsky, MD PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications or surveillance (protocol) biopsy.
Descrição
Inclusion Criteria:
- All heart transplant recipients undergoing a biopsy for clinical indications and protocol biopsies, as determined by their physician or surgeon, will be eligible to enroll in the study.
- Patients are enrolled based on standard of care biopsies, including surveillance biopsies in high-risk patients, with informed consent.
Exclusion Criteria:
- Patients will be excluded from the study if they decline participation
- Are unable to give informed consent.
- Recipients of multiple organs.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Heart transplant protocol and for cause biopsies
The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment. |
Microarray test of gene expression in heart biopsies Donor derived cell-free DNA in patient blood Centralized measurement of HLA antibodies in patient blood |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Calibration of Prospera test for T cell-mediated rejection
Prazo: 18 months
|
Set DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. Calibration of DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. |
18 months
|
|
Calibration of Prospera test for antibody-mediated rejection
Prazo: 18 months
|
Set DD-cfDNA test cut-off values against the probability of antibody-mediated rejection in the biopsy as reported by MMDx. |
18 months
|
|
Calibration of Prospera test for heart injury
Prazo: 18 month
|
Set DD-cfDNA test cut-off values against the probability of acute and chronic heart injury in the biopsy as reported by MMDx. |
18 month
|
|
Report calibrated Prospera test results for rejection
Prazo: 6 months
|
Obtain clinicians feedback |
6 months
|
|
Report calibrated Prospera test results for heart injury
Prazo: 6 month
|
Obtain clinicians feedback |
6 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determine if Prospera blood test can replace heart biopsy test
Prazo: 6 month
|
Obtain clinicians feedback |
6 month
|
|
Determine if Prospera blood test can replace follow up heart biopsy
Prazo: 6 month
|
Determine whether resolution of DD-cfDNA after treatment can monitor response to therapy and avoid follow-up biopsies |
6 month
|
|
Assessment of donor-specific antibody status
Prazo: 6 months
|
Report and compare the DSA status based on centralized and local HLA antibody measurement. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Philip F Halloran, MD PhD, Alberta Transplant Applied Genomics Center, University of Alberta
Publicações e links úteis
Publicações Gerais
- Madill-Thomsen KS, Halloran PF. Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the Molecular Microscope(R) Diagnostic System (MMDx). Clin Sci (Lond). 2024 Jun 5;138(11):663-685. doi: 10.1042/CS20220530.
- Halloran PF, Reeve J, Mackova M, Madill-Thomsen KS, Demko Z, Olymbios M, Campbell P, Melenovsky V, Gong T, Hall S, Stehlik J. Comparing Plasma Donor-derived Cell-free DNA to Gene Expression in Endomyocardial Biopsies in the Trifecta-Heart Study. Transplantation. 2024 Sep 1;108(9):1931-1942. doi: 10.1097/TP.0000000000004986. Epub 2024 Aug 20.
- Halloran PF, Madill-Thomsen KS. Donor-derived Cell-free DNA: A Step Forward in the Quest for Transplant Truth. Transplantation. 2025 Jun 1;109(6):910-914. doi: 10.1097/TP.0000000000005332. Epub 2025 Jan 28. No abstract available.
- Halloran PF, Madill-Thomsen KS. The Molecular Microscope Diagnostic System: Assessment of Rejection and Injury in Heart Transplant Biopsies. Transplantation. 2023 Jan 1;107(1):27-44. doi: 10.1097/TP.0000000000004323. Epub 2022 Dec 8.
- Madill-Thomsen KS, Hidalgo LG, Mackova M, Campbell P, Demko Z, Felius J, Gong T, Hall S, Kim DH, Kuczaj A, Lowe D, Maliakkal N, Melenovsky V, Olympios M, Patel S, Prewett A, Przybylowski P, Sayer G, Stehlik J, Tseliou E, Uriel N, Halloran PF. Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. J Heart Lung Transplant. 2026 Apr;45(4):659-670. doi: 10.1016/j.healun.2025.10.024. Epub 2025 Nov 13.
- Madill-Thomsen KS, Hidalgo LG, Mackova M, Demko Z, Prewett A, Campbell P, Felius J, Gong T, Hall S, Kim DH, Kuczaj A, Lowe D, Maliakkal N, Melenovsky V, Olympios M, Patel S, Przybylowski P, Sayer G, Tseliou E, Uriel N, Stehlik J, Halloran PF; Trifecta-Heart Study Group. Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: Results from the Trifecta-Heart study. J Heart Lung Transplant. 2026 Jul;45(7):1046-1057. doi: 10.1016/j.healun.2026.03.004. Epub 2026 Mar 13.
- Halloran PF, Madill-Thomsen KS, Biagini DG, Kaur N, Prewett A, Suresh N, Demko ZP, Bhorade S, Olympios M, Gauthier PT, Campbell PT, Gong T, Hall S, Kim DH, Kuczaj A, Przybylowski P, Melenovsky V, Patel SR, Sayer G, Stehlik J, Tseliou E, Uriel N, Mackova M; Trifecta-Heart Investigators. A two-threshold donor-derived cell-free DNA algorithm improves detection of molecular rejection in heart transplantation. J Heart Lung Transplant. 2026 Jun 22:S1053-2498(26)01953-4. doi: 10.1016/j.healun.2026.06.009. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- ATAGC06
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Only IPD data will be shared within a participating center.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .